Clinical Trial Update: Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Terminated Phase 1b/2 study of buparlisib (BKM120) in combination with trastuzumab for HER2-positive metastatic breast cancer, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BKM120 (Buparlisib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Breast Cancer, HER2+ Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-10-30